[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].
We report on a 46-year-old woman with ventricular tachycardia and ventricular fibrillation after starting antiarrhythmic drug therapy with flecainide. The flecainide acetate plasma levels were always in the normal range. A successful therapeutical intervention was induced with two i.v. applications of 1,000 mg magnesium glutamate. A persistent suppression of ventricular rhythm disturbance was accomplished by continuous i.v. application of 4 mg magnesium glutamate/min.
Mletzko
R
R
Medizinische Universitätsklinik, Innere Medizin-Kardiologie, Bonn.
Jung
W
W
Manz
M
M
Kamradt
T
T
Vogel
F
F
Lüderitz
B
B
D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000009:adverse effects* / Q000627:therapeutic use; D006350:Heart Valve Prosthesis; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000601:surgery*; D008946:Mitral Valve Stenosis / Q000601:surgery*; D011183:Postoperative Complications / Q000188:drug therapy*; D012214:Rheumatic Heart Disease / Q000601:surgery*; D013616:Tachycardia, Sinus / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000139:chemically induced* / Q000188:drug therapy
D008274:Magnesium; D005424:Flecainide
Arrhythmogener Effekt von Flecainid--Therapie mit Magnesium i.v.